Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Copy Top Investors Portfolio
Crypto Technical Analysis
Chart Pattern Signal

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SYRE
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
SYRE
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

SYRE Similar Chart Price Prediction

The price of SYRE is predicted to go up 0.28%, based on the high correlation periods with HCC. The similarity of these two price pattern on the periods is 93.52%.

stocks logo

SYRE

stocks logo

HCC

Up: 0.28%Similarity: 93.52%

SYRE Revenue Forecast

SYRE EPS Forecast

SYRE FAQs

What is bull’s view on SYRE?

SYRE stock has a bullish outlook with a price target of $65, up from $50, as per Baird's analysis. This optimism stems from better-than-expected initial data from SPY001, which de-risks its pipeline and suggests potential best-in-class efficacy in IBD. The stock's last trade at $31.27 indicates a significant upside of approximately 108%.

What is bear's view on SYRE?

SYRE stock is currently trading at $31.27, below its 200-day moving average, signaling potential bearish momentum. The recent public offering priced at $27.50 per share could exert downward pressure as the market absorbs the new shares. Additionally, the stock's high volatility within its 52-week range ($8.75–$47.97) suggests caution for investors.

What is SYRE revenue forecast for next quarter？

The market consensus for SYRE's revenue in the upcoming quarter is projected to be approximately $4M USD.

What is SYRE eps forecast for next quarter？

The market consensus for SYRE's eps in the upcoming quarter is projected to be approximately $0.82 USD.

SYRE VS S&P500

Ask Intellectia about SYRE

SYRE Analyst's Forecast

Colleen Kusy

Baird

Buy

Price Target

$50 → $65

Upside

+97.09%

Baird raised the firm's price target on Spyre Therapeutics to $65 from $50 and keeps an Outperform rating on the shares. The firm said they posted better-than-expected initial data from SPY001 and thinks the data incrementally de-risks its lead asset and broad pipeline, which could offer best-in-class dosing and potentially improved efficacy in IBD.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free